FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washinulon, D.C. 20049	D.C. 20549	hinaton.	Wa
------------------------	------------	----------	----

STATEMENT	OF CHANGE	S IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours ner resnonse.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Doyle Anthony				<u> </u>	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]						[(Ch	elationship of eck all applica Director Officer (ble)	Person	10% Ow Other (s	ner		
(Last) 4505 EM SUITE 2	IPEROR BI	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 12/14/2021						X Officer (give title below) Chief Financial (below)				
(Street) DURHA (City)		Contraction of the contraction o	27703 (Zip)	4	1. If Am	endment, Da	ate of	Original I	Filed	(Month/Day	/Year)	Line	Y Form file	ed by One	Reporti	Check Appli ing Person One Reporti		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Tra		2. Transact Date (Month/Day	Execution Date,		3. Transaction Code (Instr. 3, 4 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4		ed (A) or tr. 3, 4 and !	5. Amoun Securities Beneficial Owned Fo	Forn lly (D) o ollowing (I) (Ir		Direct I Indirect E tr. 4)	7. Nature of Indirect Beneficial Ownership						
						Code	v	Amount (A) or (D)		Price	Transaction (Instr. 3 and	tion(s)			(Instr. 4)			
Common Stock 12/2			12/14/2	021			A		115,000) ⁽¹⁾ A	\$0	208,	8,719		D			
			Table II - D			curities <i>F</i> Ils, warra							Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Date, Transaction Derivative Code (Instr. Securities		ve Expiration Date (Month/Day/Year) of Securities Underlying d (A) or d of (Instr. 3 and 4)			ties ng e Security	8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)			
Emp. Stock Option (Right to Buy)	\$11.43	12/14/2021		A		164,000 ⁽²⁾		12/14/20)22	12/14/2031	Common Stock	164,000	\$0	164,00	00	D		

Explanation of Responses:

- 1. Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- 2. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

/s/ Alane P. Barnes, by power of 12/16/2021 <u>attorney</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.